| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 137 | 155 | 159 | 180 | 166 | 179 | 185 | 178 | 175 | 203 | 209 | 221 | 223 | 237 | 238 | 266 | 254 | 284 | 300 | 316 | 335 | 352 | 357 | 393 | 402 | 447 | 448 | 467 | 447 | 479 | 522 | 554 |
| Expenses | 103 | 116 | 125 | 139 | 125 | 132 | 135 | 131 | 125 | 143 | 146 | 159 | 157 | 173 | 179 | 202 | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 | 389 | 424 |
| EBITDA | 35 | 39 | 35 | 41 | 41 | 47 | 50 | 47 | 50 | 60 | 63 | 63 | 66 | 64 | 59 | 64 | 51 | 74 | 86 | 92 | 101 | 99 | 108 | 112 | 121 | 142 | 138 | 146 | 149 | 150 | 132 | 130 |
| Operating Profit % | 23 % | 23 % | 20 % | 20 % | 23 % | 24 % | 25 % | 23 % | 27 % | 28 % | 28 % | 25 % | 26 % | 23 % | 22 % | 22 % | 19 % | 24 % | 25 % | 27 % | 27 % | 25 % | 27 % | 26 % | 27 % | 27 % | 27 % | 27 % | 26 % | 26 % | 21 % | 21 % |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 21 | 21 | 23 | 25 | 29 | 38 |
| Interest | 4 | 7 | -1 | 2 | 3 | 2 | 5 | 8 | 3 | 3 | 5 | -2 | 3 | 0 | -1 | 2 | 1 | 0 | 5 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 6 | 6 |
| Profit Before Tax | 22 | 23 | 26 | 30 | 28 | 36 | 34 | 29 | 36 | 46 | 46 | 52 | 50 | 50 | 46 | 49 | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 93 | 99 | 118 | 113 | 123 | 123 | 122 | 98 | 85 |
| Tax | 9 | 9 | 10 | 8 | 8 | 7 | 9 | 6 | 10 | 11 | 11 | 13 | 13 | 12 | 11 | 13 | 9 | 16 | 17 | 16 | 20 | 19 | 23 | 24 | 24 | 31 | 28 | 31 | 30 | 30 | 27 | 20 |
| Net Profit | 13 | 15 | 16 | 22 | 20 | 28 | 25 | 23 | 27 | 35 | 35 | 39 | 38 | 38 | 35 | 36 | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 | 71 | 65 |
| EPS in ₹ | 1.50 | 1.65 | 1.82 | 2.44 | 2.24 | 3.22 | 2.83 | 2.57 | 3.03 | 3.97 | 4.00 | 4.26 | 3.92 | 3.99 | 3.60 | 3.77 | 2.81 | 4.53 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 9.01 | 8.48 | 8.92 | 9.19 | 9.06 | 7.00 | 6.54 |
Poly Medicure
Poly Medicure
1,671.40
+108.10
(6.91%)
Market Cap
16,941.23 Cr
PE Ratio
49.39
Volume
3,21,765.00
Day High - Low
1,689.90 - 1,555.20
52W High-Low
2,316.60 - 1,182.00
Key Fundamentals
Market Cap
16,941.23 Cr
EPS
31.79
PE Ratio
49.39
PB Ratio
5.10
Book Value
306.45
EBITDA
435.51
Dividend Yield
0.22 %
Industry
Healthcare Sector
Medical Equipment Return on Equity
12.24
Debt to Equity
0.08
Analyst Rating and Forecast
- By Refinitiv from5 analysts
Actual
Company News
View All News
Poly Medicure to host investor meets
3 days ago
3 days agoPoly Medicure Limited will hold one-on-one meetings with Axis Max Life and Ikigai Asset on June 22 and 23, 2026. The meetings will be virtual and physical respectively.
Poly Medicure received a Delhi Revenue Department order demanding Rs 2.5 Cr in stamp duty and penalty. The company disputes the jurisdiction and plans legal action.
Poly Medicure Limited will hold a one-on-one meeting with Trust AMC on June 17, 2026. The session includes a plant visit in Faridabad.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,671.40 | #1 16,941.23 | #7 49.39 | #1 1,875.26 | #7 6.61 | #1 326 | #5 -29.19 | 66.47 | |
270.42 | 1,438.80 | 97.38 | 422.51 | 3.45 | 16 | -58.82 | 69.93 | |
581.75 | 1,357.12 | 23.55 | 341.74 | 5.93 | 56 | #1 750.00 | 72.80 | |
225.49 | 1,239.34 | 42.51 | 271.50 | 12.00 | 22 | 134.88 | 53.12 | |
459.15 | 812.45 | 27.85 | 292.67 | 56.84 | 30 | - | 41.47 | |
157.03 | 698.01 | #1 18.06 | 410.77 | 22.29 | 36 | 46.36 | 55.37 | |
382.00 | 662.27 | 66.09 | 278.87 | 10.97 | 10 | -68.29 | 42.20 | |
383.95 | 558.22 | 30.33 | 231.81 | #1 107.34 | 19 | - | 55.48 | |
386.20 | 463.58 | 23.08 | 71.81 | 7.02 | 21 | 13.73 | 46.77 | |
151.40 | 288.27 | 59.31 | 54.75 | -59.83 | 5 | - | 35.44 |
Growth Rate
Revenue Growth
6.61 %
Net Income Growth
-3.72 %
Cash Flow Change
-9.64 %
ROE
-30.34 %
ROCE
-30.22 %
EBITDA Margin (Avg.)
-29.37 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 | 3,919 |
| Fixed Assets | 166 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 | 1,519 |
| Current Assets | 160 | 171 | 205 | 255 | 302 | 318 | 704 | 783 | 807 | 842 | 1,917 | 1,942 |
| Capital Work in Progress | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 | 91 |
| Investments | 0 | 0 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,077 | 434 |
| Other Assets | 189 | 191 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 749 | 930 | 0 |
| Total Equity & Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 | 3,919 |
| Current Liabilities | 113 | 109 | 114 | 123 | 154 | 197 | 171 | 227 | 293 | 351 | 370 | 576 |
| Non Current Liabilities | 55 | 50 | 72 | 104 | 119 | 135 | 87 | 63 | 42 | 37 | 57 | 194 |
| Total Equity | 196 | 229 | 272 | 338 | 381 | 435 | 966 | 1,088 | 1,242 | 1,470 | 2,766 | 3,106 |
| Reserve & Surplus | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 | 3,056 |
| Share Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 | -3 |
| Investing Activities | -59 | -31 | -56 | -88 | -101 | -110 | -436 | -85 | -179 | -241 | -1,194 |
| Operating Activities | 63 | 63 | 56 | 75 | 107 | 131 | 119 | 124 | 191 | 266 | 240 |
| Financing Activities | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | 951 |
Share Holding
| % Holding | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 44.88 % | 44.88 % | 44.77 % | 44.77 % | 44.76 % | 44.66 % | 53.34 % | 53.33 % | 53.33 % | 53.31 % | 53.31 % | 53.16 % | 53.16 % | 53.15 % | 66.03 % | 62.56 % | 62.56 % | 62.44 % | 62.44 % | 62.44 % | 62.42 % | 62.42 % | 62.42 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.49 % | 0.00 % | 12.38 % | 9.91 % | 11.10 % | 11.87 % | 12.33 % | 11.46 % | 11.41 % | 9.77 % | 9.40 % | 5.91 % |
| DIIs | 1.83 % | 1.92 % | 2.68 % | 2.73 % | 2.86 % | 3.18 % | 3.10 % | 3.20 % | 3.38 % | 3.68 % | 4.25 % | 5.15 % | 5.28 % | 7.22 % | 9.35 % | 12.48 % | 12.33 % | 11.66 % | 11.96 % | 11.72 % | 13.54 % | 13.84 % | 15.59 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 15.11 % | 14.24 % | 13.69 % | 13.24 % | 12.32 % | 11.93 % | 11.20 % | 11.18 % | 11.12 % | 11.10 % | 11.35 % | 11.38 % | 11.34 % | 11.37 % | 10.70 % | 10.14 % | 10.55 % | 11.08 % | 11.37 % | 11.25 % | 11.30 % | 12.61 % |
| Others | 37.06 % | 38.10 % | 38.30 % | 38.81 % | 39.14 % | 39.84 % | 31.63 % | 32.27 % | 32.11 % | 31.90 % | 31.34 % | 15.85 % | 30.17 % | 15.92 % | 3.36 % | 3.16 % | 3.10 % | 3.03 % | 3.07 % | 3.07 % | 3.02 % | 3.04 % | 3.47 % |
| No of Share Holders | 0 | 19,187 | 21,531 | 35,922 | 33,678 | 35,166 | 33,831 | 33,296 | 34,239 | 35,393 | 36,141 | 34,649 | 36,053 | 36,712 | 36,852 | 40,516 | 38,352 | 60,686 | 65,583 | 71,142 | 64,400 | 67,750 | 73,414 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 2.5 | 2 | 2 | 2 | 2.5 | 2.5 | 3 | 3 | 3.5 | 0.00 |
| Dividend Yield (%) | 1 | 0.91 | 0.86 | 0.24 | 0.26 | 0.27 | 0.19 | 0.13 | 0.29 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Mar 2017 |  Bonus | 1:1 | 24 Mar 2017 | 0.00 | 0.00 |
| 17 Sept 2021 |  Dividend | ₹ 2.50 /share | 16 Sept 2021 | 1,133.15 | 955.00 |
| 19 Sept 2022 | Dividend | ₹ 2.50 /share | 16 Sept 2022 | 715.55 | 933.00 |
| 22 Sept 2023 | Dividend | ₹ 3.00 /share | 21 Sept 2023 | 977.25 | 1,413.65 |
| 20 Sept 2024 | Dividend | ₹ 3.00 /share | 19 Sept 2024 | 1,654.70 | 2,462.65 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 2,498.45 | 2,318.00 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 2,450.95 | 2,514.10 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 2,445.25 | 2,433.90 |
| 06 May 2025 | Quarterly Result Announcement | NA | 06 May 2025 | 2,587.85 | 2,584.60 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 2,057.40 | 1,931.65 |
| 18 Sept 2025 | Dividend | ₹ 3.50 /share | 18 Sept 2025 | 2,584.60 | 1,996.60 |
| 25 Sept 2025 | Annual General Meeting | NA | 25 Sept 2025 | 2,067.00 | 1,981.35 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 1,974.45 | 1,893.80 |
| 05 Feb 2026 | Quarterly Result Announcement | NA | 05 Feb 2026 | 1,515.85 | 1,517.95 |
| 25 May 2026 | Quarterly Result Announcement | NA | 25 May 2026 | 1,598.75 | 1,598.20 |
Announcements
Intimation For The Schedule Of Investor/Analyst Call/Meet1 hr ago
1 hr agoIntimation For The Schedule Of Investors/Analysts Call/Meet3 days ago
3 days agoThe Company Is In Receipt Of An Order Passed By Office Of Divisional Commissioner Government Of The NCT Of Delhi Revenue Department: Stamp & Registration Branch Through The Collector Of Stamps5 days ago
5 days agoIntimation Of Investor/Analyst Meet10 days ago
10 days agoInvestors/Analysts Meet ScheduleJun 10, 2026
Jun 10, 2026Intimation Of Analyst/Investor MeetJun 03, 2026
Jun 03, 2026Intimation For The Analyst/Investors MeetJun 02, 2026
Jun 02, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJun 01, 2026
Jun 01, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 29, 2026
May 29, 2026Investors Call Scheduled To Be Held On 27 May 2026 Is Cancelled - Updates On CallMay 26, 2026
May 26, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 26, 2026
May 26, 2026Declaration Of Unmodified Opinion On The Audited Financial Results(Standalone & Consolidated) For The Quarter And Year Ended For The 31St March 2026May 25, 2026
May 25, 2026Statement Of Deviation & Variation For The Quarter Ended On 31St March 2026May 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 25, 2026
May 25, 2026Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March 2026May 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 25, 2026
May 25, 2026Board Meeting Outcome for Poly Medicure Limited Has Submitted To The Exchange The Audited Financial Results(Standalone & Consolidated) For The Quarter And Year Ended March 31 2026.May 25, 2026
May 25, 2026Grant Of Stock Options- Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015May 23, 2026
May 23, 2026Intimation Of Investor/Analyst CallsMay 21, 2026
May 21, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2026
May 15, 2026Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 25Th May 2026May 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-AcquisitionApr 30, 2026
Apr 30, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2026
Apr 15, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call Schedule On 30Th March 2026Mar 25, 2026
Mar 25, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call Schedule On 24Th March 2026 And Cancellation Of Investors/Analysts Call Scheduled On 20Th March 2026Mar 19, 2026
Mar 19, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call/Meet On 20Th March 2026Mar 17, 2026
Mar 17, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call/Meet On 19Th March 2026Mar 12, 2026
Mar 12, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call/Meet On 18Th March 2026Mar 10, 2026
Mar 10, 2026Poly Medicure Limited Has Informed The Exchange About Investors/Analysts Call/Meet On 09Th March 2026 And 10Th March 2026.Mar 07, 2026
Mar 07, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMar 07, 2026
Mar 07, 2026Intimation Of Analysts/Investors Meet To Be Held On 9Th And 10Th March 2026Mar 03, 2026
Mar 03, 2026Intimation Of Analysts/Investors Meet To Be Held On 6Th March 2026Mar 02, 2026
Mar 02, 2026Intimation Of Analysts/Investors Call To Be Held On 02Nd March 2026Feb 28, 2026
Feb 28, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 13, 2026
Feb 13, 2026Statement Of Deviation And Variation For The Quarter Ended 31St December 2025Feb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 05, 2026
Feb 05, 2026Grant Of 2000 Stock Options Under ESOS 2020 Of The Company.Feb 05, 2026
Feb 05, 2026Unaudited Financial Results (Standalone & Consolidated) For The Third Quarter And Nine Months Ended On 31St December 2025.Feb 05, 2026
Feb 05, 2026Board Meeting Outcome for Otcome Of Board Meeting Held On Today I.E. 05Th February 2026Feb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2026
Jan 31, 2026Board Meeting Intimation for Intimation For The Board Meeting To Be Held On 05Th February 2026 For Consider And Approve The Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended On 31St December 2025.Jan 29, 2026
Jan 29, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 58.75
ATR(14)
Less Volatile 63.56
STOCH(9,6)
Overbought 89.68
STOCH RSI(14)
Overbought 98.34
MACD(12,26)
Bullish 19.08
ADX(14)
Weak Trend 18.96
UO(9)
Bearish 63.87
ROC(12)
Uptrend And Accelerating 16.73
WillR(14)
Overbought -10.65
About Poly Medicure
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and...more
Website
Chairperson NameDevendra Raj Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
